SOURCE: Equity Markets Inc.

November 07, 2011 09:00 ET

Professional Outlook, Will EU's Deal Hold the Markets? - Equity Research on Acorda Therapeutics Inc. and BioMarin Pharmaceutical Inc.

MACAU--(Marketwire - Nov 7, 2011) - Today, announced its research report highlighting Acorda Therapeutics Inc. (NASDAQ: ACOR) and BioMarin Pharmaceutical Inc. (NASDAQ: BMRN). Full content and research is available at

Markets are starting to step in the right direction, with the European Financial Stability Facility (EFSF) increasing from $600 billion to $1.4 trillion, a significant move to strengthen the safety net in place for Europe's most troubled countries.

It is likely China and the IMF will contribute to the bailout fund, with Greece alone receiving $180 billion in fresh aid. The remainder of Greece's obligations were halved in the process, with private bondholders of Greek debt settling at 50% -- allowing banks to recapitalize at a healthy 9% reserve and bring Greece's debt burden down to 120% of GDP by 2020.

An important consideration is political commitment to this road map and probability of ongoing support for European Central Bank (ECB)'s recent deal. Currently the global community appears to be on point with ECB's initiative, an outlook that should be sufficient to support markets around current levels.

Equity Markets has reviewed Acorda Therapeutics Inc. for its current position within the healthcare industry. Acorda Therapeutics, Inc. (Acorda) is a commercial-stage biopharmaceutical company engaged in the identification, development and commercialization of therapies that improve neurological function in people with multiple sclerosis (MS), spinal cord injury (SCI), and other disorders of the nervous system. The full research report on Acorda Therapeutics Inc. (NASDAQ: ACOR) is available here:

Equity Markets has reviewed BioMarin Pharmaceutical Inc. for its development within the healthcare industry. BioMarin Pharmaceutical Inc. (BioMarin) develops and commercializes pharmaceuticals for serious diseases and medical conditions. The Company's product portfolio consists of four approved products and multiple investigational product candidates. The full research report on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) is available here:

About Equity Markets
Our mission at Equity Markets is to be the best source of content and research, while educating, enlightening and informing investors. Equity Markets combines street smart analysts and professional market researchers to provide investors with detailed company profiles and market coverage.

Contact Information